オリンパス（7733） – 2022年３月期　第３四半期　決算参考資料

2022年3⽉期　第3四半期　決算参考資料Financial Data for the 3rd quarter of FY2022The FY2022, the year ending March 31, 2022April 1, 2021 – March 31, 20221. 連結決算概要 / Consolidated Financial Summary2. セグメント別情報 / Information by Business Segment(1) 医療分野 / Medical BusinessESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division)(2) 科学事業 / Scientific Solutions Division(3) その他 / Others(4) 全社消去 / Corporate Expenses3. 連結財政状態計算書 / Consolidated Statement of Financial Position4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows5. 会社概要 / Corporate Outline3,4,52677889（本資料における留意点について）（Notes regarding this material)・本資料のうち、業績⾒通し等は、現在⼊⼿可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が⽬標と⼤きく異なる可能性があります。・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利⽤は、他の⽅法により⼊⼿された情報とも照合確認し、利⽤者の判断によって⾏ってくださいますようお願い致します。・本資料利⽤の結果⽣じたいかなる損害についても、当社は⼀切責任を負いません。・⽇本産業パートナーズ株式会社が設⽴した特別⽬的会社に対して、2021年1⽉1⽇に映像事業を譲渡しました。これに関し、2021年3⽉期第2四半期連結会計期間より、映像事業を⾮継続事業に分類し、過去に開⽰した以下の数値も組み替えて表⽰しています。　連結損益計算書︓「2021年3⽉期第1四半期（3カ⽉）」・2022年3⽉期より、内視鏡事業の消化器内視鏡分野に分類していた気管⽀鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、過去に開⽰した以下の数値も組み替えて表⽰しています。　セグメント別情報（ESD/TSD）︓「2021年3⽉期第1四半期（3カ⽉）、第2四半期（3カ⽉）、第3四半期（3カ⽉）、第3四半期累計（9カ⽉）、第4四半期（3カ⽉）、通期」・2021年3⽉期に発⽣したVeran Medical Technologies社、Quest Photonic Devices社の企業結合について、第１四半期連結会計期間、第２四半期連結会計期間及び当第3四半期連結会計期間において暫定的な⾦額の修正を⾏っています。これに伴い、過去に開⽰した以下の数値の遡及的な修正を⾏っています。　連結財政状態計算書︓「2021年3⽉期　3⽉31⽇時点」・This material contains forward-looking statements that reflect managementʼs current views, plans, and expectations basedon information available at the time of preparation. These forward-looking statements are not guarantees of futureperformance and involve known and unknown risks, uncertainties, future business decisions, and other internal and externalfactors that may cause the Companyʼs actual results, performance, achievements, or financial position to be materiallydifferent from any future results expressed or implied by these forward-looking statements.・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition tothis material when making investment decisions.・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.・Olympus Corporation split off the imaging business to a special purpose company established by Japan Industrial Partners,Inc. on Janualy 1, 2021. In this regard, imaging division is categolized as a discontinued operation, effective Q2 of FY2021and figures for below accounting periods are restated. Consolidated Statements of Profit or Loss: FY2021.Q1 (3M)・From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have beentransferred into the respiratory segment of TSD. Accordingly, we restated figures for below accounting periods. Information by Business Segment (ESD/TSD): FY2021.Q1 (3M), FY2021.Q2 (3M), FY2021.Q3 (3M), FY2021.Q3 total (9M),FY2021.Q4 (3M), FY2021 (total)・Regarding acquisitions with Veran Medical Technologies and Quest Photonic Devices B.V. that occurred in FY2021, there weretemporary revisions in amounts during Q1, Q2 and Q3 of FY2022. In line with this, the following figures disclosed in the pasthave been retroactively revised. Consolidated statement of financial position: As of March 31, FY20211１．連結決算概要 / Consolidated Financial Summary■連結損益計算書概要 / Summary of Consolidated Statements of Profit or LossFY2021項⽬Item百万円（\ million）FY2022Q3FY2022As of Nov 5Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 Total Total forecast136,650 179,850 197,084 513,584 216,960 730,544 191,517 221,542 216,698 629,757 862,000856,000売上⾼Revenue売上原価Cost of sales売上総利益Gross profit販売費及び⼀般管理費S.G.A. expensesその他の収益および費⽤等Other income and expenses etc.営業利益Operating profit⾦融収益および費⽤Finance income and costs税引前利益Profit before tax法⼈所得税費⽤Income taxes継続事業からの当期利益 (損失)Profit (loss) from continuing operation⾮継続事業からの当期利益(損失)Profit (loss) from discontinued operation当期利益(損失)Profit (loss)親会社の所有者に帰属する当期利益(損失)Profit (loss) attributable to owners of parent売上総利益率Gross profit ratio販管費率S.G.A. ratio営業利益率Operating profit margin親会社の所有者に帰属する当期利益率Profit (loss) attributable to owners of parent51,39869,14469,548 190,09080,924 271,01468,20174,60075,117 217,918 295,000295,00085,252 110,706 127,536 323,494 136,036 459,530 123,316 146,942 141,581 411,839 567,000561,00080,33281,12688,719 250,177 106,855 357,03295,79795,662 102,160 293,619 405,000400,000-1,211-2,997-4,375-8,583 -11,930 -20,51393-2,636-6,767-9,310 -18,000-17,0003,70926,58334,44264,73417,25181,98527,61248,64432,654 108,910 144,000144,000-1,015-946-855-2,816-2,359-5,175-660-1,750-2,865-5,275-5,000-5,0002,69425,63733,58761,91814,89276,81026,95246,89429,789 103,635 139,000139,0002,868-4145,5327,9863,15411,1408,2063,1274,45315,78630,00030,000-17426,05128,05553,93211,73865,67018,74643,76725,33687,849 109,000109,000-2,558 -45,996-3,733 -52,287-394 -52,681——-2,732 -19,94524,3221,64511,34412,98918,74643,76725,33687,849 109,000109,000-2,736 -19,96624,3261,62411,29412,91818,69043,70725,27087,667 109,000109,00062.4% 61.6% 64.7% 63.0% 62.7% 62.9% 64.4% 66.3% 65.3% 65.4% 65.8%65.5%58.8% 45.1% 45.0% 48.7% 49.3% 48.9% 50.0% 43.2% 47.1% 46.6% 47.0%46.7%2.7% 14.8% 17.5% 12.6%8.0% 11.2% 14.4% 22.0% 15.1% 17.3% 16.7%16.8%–12.3%0.3%5.2%1.8%9.8% 19.7% 11.7% 13.9% 12.6%12.7%EBITDAEBITDAマージンEBITDA margin* FY2021Q2より映像事業を⾮継続事業に分類しています。⾮継続事業からの利益は継続事業と区分し、「売上⾼」から「継続事業からの当期利益(損失)」までは継続事業の⾦額を表⽰しています。/ From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operation. From “revenue” to “profit (loss) from continuing operation” in the above table are amounts related to continuing operation only. 13.9% 22.4% 25.2% 21.2% 15.1% 19.4% 22.6% 29.2% 22.5% 24.9% 23.9%49,674 108,85048,772 156,903141,544206,00064,78040,21643,35132,69418,960206,00024.1%■投資他 / Expenditures etcQ1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 Total Total forecast百万円（\ million）FY2022Q3FY2022As of Nov 515,251減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expenditures開発費資産化Capitalization of R&D expenditures*上表の数値は継続事業の⾦額を表⽰しています。/ Amounts in the above table are related to continuing operation only. 14,91613,63315,23216,67317,87124,53221,14619,58444,11615,44356,12142,81458,60123,19311,5713,4153,9974,1594,56359,55915,73916,13616,11847,99362,00062,00098,93516,89418,13619,50954,53978,00078,00081,79420,42220,33821,76962,52985,00087,00016,1343,8034,3844,17312,36016,00018,000■為替 / Foreign exchange円/USD（期中平均レート）Yen/U.S. dollar (Average rate)円/EUR（期中平均レート）Yen/Euro (Average rate)円/CNY（期中平均レート）Yen/Renminyuan (Average rate)Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 Total Total forecast107.62106.22104.51106.11105.90106.06109.49110.11113.71111.10FY2022Q3118.48124.11124.54122.38127.69123.70131.96129.84130.07130.6215.1715.3515.8115.4416.3615.6716.9617.0217.7817.25売上⾼に対する為替影響額FX Impact on revenue営業利益に対する為替影響額FX Impact on operating profit*上表の数値は継続事業の⾦額を表⽰しています。/ Amounts in the above table are related to continuing operation only. -5,381-1,732-2,968-8,425-2,968-5,639-1,3152,150-939-76-6,27510,80210,10714,30135,210-6,9544293,6982,6726,799■為替感応度（年間） / Foreign exchange sensitivity (Annual basis)　億円 （\ 100 million）FY2022As of Nov 51101301711213017–FY2021FY2021売上⾼Revenue営業利益Operating profit23166810745ドル（1円あたり）U.S. dollar（Per 1JPY）ユーロ（1円あたり）Euro（Per 1JPY）⼈⺠元（1円あたり）Renminyuan（Per 1JPY）■従業員数 / Number of employees連結Consolidated内視鏡事業Endoscopic Solutions Division治療機器事業Therapeutic Solutions Division医療分野Medical BusinessFY2021FY2022As of Mar 31As of Jun 30As of Sep 30As of Dec 31As of Mar 3131,653 (18,100) 31,191 (17,984) 31,073 (18,085) 31,179 (18,275)13,436(7,225) 13,759(7,352) 13,693(7,352) 13,694(7,419)8,076(5,427)7,761(5,212)7,868(5,336)7,926(5,392)21,512 (12,652) 21,520 (12,564) 21,561 (12,688) 21,620 (12,811)————科学事業Scientific Solutions Divisionその他、全社Others, Corporate* 上表の従業員数は正社員のみでパートは含まれておりません。 / The number of temporary employees is not included in the number of employees.(3,281)(3,252)(2,167)(3,265)(2,155)(2,145)6,5903,6206,0485,9063,5513,6233,6065,939(2,154)(3,310)* 2021年3⽉31⽇時点の従業員数には、社外転進⽀援制度を利⽤して退職する842名を含めております。 / The number of employees as of March 31, 2021 includes 842 employees who retire using the career support for external opportunity.*（ ）は海外従業員数です。 / （）:Number of overseas employees* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管⽀鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、2021年3⽉31⽇時点の従業員数も組み替えて表⽰しています。 / From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD. Accordingly, we restated the number of employees as of March 31, 2021.* FY2022 9⽉30⽇時点の治療機器事業の従業員数に誤りがあったため、数値を遡及して修正しています。 / Due to an error in the number of employees in TSD as of September 30, FY2022, the figures have been retroactively revised.項⽬Item項⽬Item項⽬Item項⽬Item22. セグメント別情報 / Information by Business Segment（1）医療分野 / Medical Business* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管⽀鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、FY2021Q1、Q2、Q3、Q3累計、Q4、通期の数値も組み替えて表⽰しています。/ From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD. Accordingly, we restated figures for FY2021Q1, Q2, Q3, Q3 total, Q4, total. ■ESD 損益 / Revenue and Operating profit of ESD 百万円（\ million）Q1Q2Q3Q3 TotalQ4TotalQ1Q2FY2021FY2022Q3FY2022Q3 Total Total forecast As of Nov 574,31697,005 105,358 276,679 116,985 393,664 100,014 120,551 113,136 333,701 459,000453,00012,41729,92131,58073,91824,85398,77122,65438,99129,95591,600 131,000127,000その他の損益Other income and expenses-367-159-780-1,306-4,626-5,932-2,153-952-887-3,992–16.7% 30.8% 30.0% 26.7% 21.2% 25.1% 22.7% 32.3% 26.5% 27.4% 28.5%28.0%34.6% 24.3%7.4% 20.6% 16.6%82.4% 30.3% -5.1% 23.9% 32.6%■TSD 損益 / Revenue and Operating profit of TSD Q1Q2Q3Q3 TotalQ4TotalQ1Q2FY2021百万円（\ million）FY2022Q3FY2022Q3 Total Total forecast As of Nov 542,98258,65462,316 163,95267,890 231,84263,64669,45570,613 203,714 277,000276,0003,6636,26113,24323,1677,40030,56714,07216,19013,58343,84557,00055,000その他の損益Other income and expenses-285-109-340-734-2,218-2,9522,538-422-8331,283–8.5% 10.7% 21.3% 14.1% 10.9% 13.2% 22.1% 23.3% 19.2% 21.5% 20.6%19.9%48.1% 18.4% 13.3% 24.3% 19.5%284.2% 158.6%2.6% 89.3% 86.5%■医療分野 損益 / Revenue and Operating profit of Medical BusinessFY2021Q1Q2Q3Q3 TotalQ4TotalQ1Q2117,298 155,659 167,674 440,631 184,875 625,506 163,660 190,006 183,749 537,415 736,000729,000百万円（\ million）FY2022Q3FY2022Q3 Total Total forecast As of Nov 516,08036,18244,82397,08532,253 129,33836,72655,18143,538 135,445 188,000182,000その他の損益Other income and expenses-652-268-1,120-2,040-6,844-8,884385-1,374-1,720-2,709–13.7% 23.2% 26.7% 22.0% 17.4% 20.7% 22.4% 29.0% 23.7% 25.2% 25.5%25.0%項⽬Item売上⾼Revenue営業利益Operating profit営業利益率Operating profit margin売上⾼対前年⽐Revenue (YoY)営業利益対前年⽐Operating profit (YoY)項⽬Item売上⾼Revenue営業利益Operating profit営業利益率Operating profit margin売上⾼対前年⽐Revenue (YoY)営業利益対前年⽐Operating profit (YoY)項⽬Item売上⾼Revenue営業利益Operating profit営業利益率Operating profit margin売上⾼対前年⽐Revenue (YoY)営業利益対前年⽐Operating profit (YoY)39.5% 22.1%9.6% 22.0% 17.7%128.4% 52.5% -2.9% 39.5% 45.4%■ESD 投資他 / Expenditures etc of ESD Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal8,0536,4917,38921,9337,48829,4217,9838,2788,57924,840百万円（\ million）FY2022Q37,9648,75310,04126,75824,12050,87810,5048,78210,26729,5536,9489,1249,09325,1659,79234,9579,1779,03310,68728,897■TSD 投資他 / Expenditures etc of TSD Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal3,3893,3123,79610,4974,00714,5043,8774,0894,47212,438百万円（\ million）FY2022Q32,5263,36811,78017,6746,69224,3662,8354,2135,45712,5054,1485,0844,48213,7145,76919,4834,7805,0615,37915,220■医療分野 投資他 / Expenditures etc of Medical BusinessQ1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal11,4429,80311,18532,43011,49543,92511,86012,36713,05137,278百万円（\ million）FY2022Q310,49012,12121,82144,43230,81275,24413,33912,99515,72442,05811,09614,20813,57538,87915,56154,44013,95714,09416,06644,117減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expenditures減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expenditures項⽬Item項⽬Item項⽬Item減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expendituresFY2021FY2021FY2021———3■ESD 地域別売上⾼ / Revenue by Region of ESD FY2021Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal9,83215,35014,47639,65720,49060,14813,54317,72215,57246,837百万円（\ million）FY2022Q326,38531,30435,39593,08439,422 132,50637,35339,44438,449 115,24619,15724,17029,07972,40728,704 101,11125,06029,49331,21385,76611,37816,43016,10743,91516,15860,07313,71721,11814,41049,2456,4658,2198,34723,0319,56232,5938,59010,39510,47329,4581,0991,5321,9544,5852,6497,2331,7512,3793,0197,14974,31697,005 105,358 276,679 116,985 393,664 100,014 120,551 113,136 333,701■TSD 地域別売上⾼ / Revenue by Region of TSD FY2021Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal8,56610,36411,23230,16211,37941,54110,21311,94611,86834,027百万円（\ million）FY2022Q313,38221,04221,21455,63823,28778,92523,94525,16725,20174,31310,58714,44216,42041,45017,73759,18516,54216,27720,14852,9676,1997,6007,58921,3889,59430,9826,9529,7786,73323,4633,7154,6874,98013,3824,91118,2935,1875,2495,52915,9655335198811,9329822,9168071,0381,1342,97942,98258,65462,316 163,95267,890 231,84263,64669,45570,613 203,714■医療分野 地域別売上⾼ / Revenue by Region of Medical Business百万円（\ million）Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal18,39825,71425,70869,81931,869 101,68923,75629,66827,44080,864FY2021FY2022Q339,76752,34656,609 148,72262,709 211,43161,29864,61163,650 189,55929,74438,61245,499 113,85746,441 160,29641,60245,77051,361 138,73317,57724,03023,69665,30325,75291,05520,66930,89621,14372,70810,18012,90613,32736,41314,47350,88613,77715,64416,00245,4231,6322,0512,8356,5173,63110,1492,5583,4174,15310,128117,298 155,659 167,674 440,631 184,875 625,506 163,660 190,006 183,749 537,415項⽬Item⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceaniaその他Others合計Total項⽬Item⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceaniaその他Others合計Total項⽬Item⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceaniaその他Others合計Total———————■ESDサブセグメント別売上占有率 / Sub-segment Sales Ratio within ESD(FY2022 Q3 Total )消化器内視鏡Gastrointestinal Endoscope外科内視鏡Surgical Endoscope医療サービスMedical Service約Approx.約Approx.55%10%30%約Approx.■TSDサブセグメント別売上占有率 / Sub-segment Sales Ratio within TSD(FY2022 Q3 Total )消化器科（処置具）GI-Endotherapy泌尿器科Urology呼吸器科Respiratoryその他の治療領域Other Therapeutic Areas約Approx.30%30%15%25%約Approx.約Approx.約Approx.* 四捨五⼊のため、合計値が100%にならないことがあります。/ Due to rounding, the total may not add up to 100%.4■現地通貨別成⻑率 / Growth Rate of Medical Segment on Constant Currency Basis(為替影響調整後前年同期⽐ / After foreign exchange adjustment YoY)Q1Q2Q3Q3 TotalTotal38% (38%)15% (15%)8%(8%)18% (18%)FY2022項⽬Item⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceania分野計Total⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceania分野計Total⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceania分野計Total医療分野Medical BusinessESDTSDESDTSD38% (38%)22% (22%)-1% (-1%)18% (18%)18% (17%)15% (15%)0%(0%)10% (10%)8%(8%)16% (16%)-21% (-21%)0%(0%)21% (21%)20% (20%)20% (20%)20% (20%)27% (27%)18% (18%)0%(0%)14% (14%)19% (19%)15% (15%)6%(6%)13% (13%)75% (67%)15% (12%)9%(8%)27% (23%)40% (40%)7%(7%)15% (15%)19% (19%)1%(1%)16% (16%)-22% (-22%)-2% (-2%)26% (26%)6%(6%)6%(6%)12% (12%)40% (37%)13% (12%)6%(6%)17% (16%)29% (29%)15% (15%)7%(7%)16% (16%)50% (48%)19% (18%)3%(2%)21% (20%)26% (25%)12% (12%)5%(5%)13% (13%)6%(6%)16% (16%)-21% (-21%)0%(0%)23% (23%)15% (15%)15% (15%)17% (17%)32% (31%)16% (16%)2%(2%)15% (15%)* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管⽀鏡につきまして、治療機器事業の呼吸器科に移管しています。 これに伴い、FY2022Q1以降は組替後の成⻑率を表⽰、FY2021の成⻑率は⾮開⽰といたします。/ From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD. Accordingly, the reclassified growth rates are shown from the Q1 of FY2022. Growth rates for FY2021 are not disclosed.* ():Veran Medical Technologies社、Quest Photonic Devices、Medi-Tate社の買収による売上の影響を除く、オーガニックベース / ():Organic Basis, excluding the impact of sales from the acquisitions of Veran Medical Technologies, Inc., Quest Photonic Devices B.V., and Medi-Tate Ltd.■サブセグメント別成⻑率 / Growth Rate by Sub-segment(為替影響調整後前年同期⽐ / After foreign exchange adjustment YoY)項⽬Item消化器内視鏡Gastrointestinal Endoscope外科内視鏡Surgical Endoscope医療サービスMedical Service分野計Total消化器科（処置具）GI-Endotherapy泌尿器科Urology呼吸器科Respiratoryその他の治療領域Other Therapeutic Areas分野計TotalQ1Q2Q3Q3 TotalTotal38% (38%)23% (23%)-3% (-3%)16% (16%)FY202228% (27%)17% (17%)9%(9%)17% (16%)11% (11%)10% (10%)2%(2%)8%(8%)27% (27%)18% (18%)0%(0%)14% (14%)32% (32%)9%(9%)6%(6%)14% (14%)60% (60%)13% (13%)11% (11%)24% (24%)33% (19%)29% (21%)4%(2%)21% (13%)34% (34%)9%(9%)3%(3%)13% (13%)40% (37%)13% (12%)6%(6%)17% (16%)* ():Veran Medical Technologies社、Quest Photonic Devices、Medi-Tate社の買収による売上の影響を除く、オーガニックベース / ():Organic Basis, excluding the impact of sales from the acquisitions of Veran Medical Technologies, Inc., Quest Photonic Devices B.V., and Medi-Tate Ltd.—————————52. セグメント別情報 / Information by Business Segment（2）科学事業 / Scientific Solutions Division■損益 / Revenue and Operating profitFY2021Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 Total Total forecast17,75722,55526,62966,94128,92095,86124,82928,33229,69382,854 114,000114,000百万円（\ million）FY2022Q3FY2022As of Nov 5-1,6041,8272,7332,9561,9934,9491,8734,6124,87611,36115,50015,500その他の損益Other income and expenses-313349-1719-1,263-1,244-183-105-206-494—8.1% 10.3%4.4%6.9%5.2%7.5% 16.3% 16.4% 13.7% 13.6%13.6%39.8% 25.6% 11.5% 23.8% 18.9%- 152.4% 78.4% 284.3% 213.2%百万円（\ million）FY2022Q3■投資他 / Expenditures etc項⽬Item減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expenditures■地域別売上⾼ / Revenue by Region項⽬ItemFY2021FY2021Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal1,6991,7831,9985,4801,8337,3131,7161,7911,6975,2041,3671,7331,2784,3784,7209,0981,4252,0852,1905,7001,7382,2961,9295,9632,9998,9621,9712,7052,5137,189Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal2,0613,2803,0658,4066,39314,7982,5264,3933,39710,316百万円（\ million）FY2022Q34,5925,8536,86917,3148,07025,3846,9207,5438,21622,6793,1784,2125,80113,1905,94119,1324,4135,3786,19115,9824,3535,1735,92915,4553,82219,2775,5095,5146,08017,1032,7242,9653,5259,2143,23812,4523,8603,8084,07011,7388491,0721,4403,3621,4564,8181,6011,6961,7395,03617,75722,55526,62966,94128,92095,86124,82928,33229,69382,854■サブセグメント別売上占有率 / Sub-segment Sales Ratio(FY2022 Q3 Total )ライフサイエンスLife Science産業Industrial約Approx.40%60%約Approx.■サブセグメント別成⻑率 / Growth Rate by Sub-segment(為替影響調整後前年同期⽐ / After foreign exchange adjustment YoY)FY2021項⽬ItemQ1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotalFY2022Q322%13%0%10%39%26%7%22%32%20%4%17%項⽬Item売上⾼Revenue営業損益Operating profit (loss)営業利益率Operating profit margin売上⾼対前年⽐Revenue (YoY)営業利益対前年⽐Operating profit (YoY)⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceaniaその他Others合計TotalライフサイエンスLife Science産業Industrial分野計Total————-62. セグメント別情報 / Information by Business Segment（3）その他 / Others■損益 / Revenue and Operating profit売上⾼Revenue営業損益Operating profit (losses)その他の損益Other income and expenses営業利益率Operating profit margin2-項⽬ItemQ1Q2Q3Q3 TotalQ4TotalQ1Q2FY2021百万円（\ million）FY2022Q3FY2022Q3 Total Total forecast As of Nov 51,5951,6362,7816,0123,1659,1773,0283,2043,2569,48812,00013,000-518-443-570-1,531849-682-565-573-350-1,488-2,500-2,500-2622-21,5341,53231-40616-359——-89.8% 95.8% 17.1% 57.8% 30.8%——売上⾼対前年⽐Revenue (YoY)営業利益対前年⽐Operating profit (YoY)* FY2021Q2より映像事業を⾮継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表⽰しています。/ From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1. -Q1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal百万円（\ million）FY2022Q3■地域別売上⾼ / Revenue by Region項⽬ItemFY20212452332,0031,5201,504⽇本Japan北⽶North America欧州Europe中国Chinaアジア・オセアニアAsia and Oceaniaその他Others合計Total* FY2021Q2より映像事業を⾮継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表⽰しています。/1,5951,6362,7816695253671213244—101725,0271,9406,9671,8122,0751,9865,873109551646138441436941,1051,7991,0919921,1523,2351253222251450297116327210——-6,0123,1659,1773,0283,2043,2569,488 From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1. （4）全社消去 / Corporate expenses■損益 / Revenue and Operating profit売上⾼Revenue営業損益Operating profit (losses)その他の損益Other income and expensesQ1Q2Q3Q3 TotalQ4TotalQ1Q2FY2021百万円（\ million）FY2022Q3FY2022Q3 Total Total forecast As of Nov 5– – – – ——10,249 -10,983 -12,544 -33,776 -17,844 -51,620 -10,422 -10,576 -15,410 -36,408 -57,000-51,000-276-3,105-3,386-6,767-5,745 -12,512-175-1,115-5,035-6,325- -* FY2021Q2より映像事業を⾮継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表⽰しています。/ From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1. ■投資他 （その他・全社消去） / Expenditures etc（Others, Corporate expenses)百万円（\ million）減価償却費Depreciation and amortization資本的⽀出Capital expenditures研究開発⽀出R&D expendituresQ1Q2Q3Q3 TotalQ4TotalQ1Q2Q3 TotalTotal2,1102,0472,0496,2062,1158,3212,1631,9781,3705,511FY2022Q3FY20213,0592,8191,4337,3117,28214,5932,1303,0561,5956,7815,0374,6424,08013,7594,63318,3924,4943,5393,19011,223項⽬Item項⽬Item—————73. 連結財政状態計算書 / Consolidated statement of financial positionFY2021百万円（\ million）FY2022As ofJun 30As ofSep 30As ofDec 31As ofMar 31As ofJun 30As ofSep 30As of Dec 31As of Mar 311,099,0811,073,5421,105,2211,183,4531,144,6061,185,3021,292,967項⽬Item資産Assets　流動資産　　Current assets　　　　現⾦及び現⾦同等物　　　　Cash and cash equivalents　　　　棚卸資産　　　　Inventories売却⽬的で保有する資産Assets held for sale　　　　その他　　　　Others　⾮流動資産　　Non-current assets負債Liabilities　流動負債　　Current liabilities売却⽬的で保有する資産に直接関連する負債Liabilities directly associated withassets held for sale　⾮流動負債　　Non-current liabilities資本Equity親会社の所有者に帰属する持分Total equity attributable to owners ofparentその他Others604,400571,170553,935580,073513,399552,314657,331270,506185,618163,420217,478168,713193,435275,090183,318160,857159,457158,895164,057 166,047166,9586,10032,63825,027117435– 144,476192,057206,031203,583180,194192,832215,283494,681502,372551,286603,380631,207632,988635,636737,126745,956749,384787,973743,228738,071812,673344,410303,612295,618328,391282,670288,236333,2874,09328,99625,027-1,056–392,716442,344453,766459,582460,558449,835479,386361,955327,586355,837395,480401,378447,231480,294360,910326,520354,775394,326400,356446,149479,1461,0451,0661,0621,1541,0221,0821,148————–382,732395,920有利⼦負債Interest-bearing debt純有利⼦負債Net debt⾃⼰資本⽐率Equity ratio* FY2021に発⽣したVeran Medical Technologies社、Quest Photonic Devices社の企業結合について、FY2022Q1、Q2及びQ3において暫定的な⾦額の修正を⾏っています。 これに伴い、FY2021 3⽉31⽇時点の数値を遡及して修正しています。/ Regarding acquisitions with Veran Medical Technologies and Quest Photonic Devices B.V. that occurred in FY2021, there were temporary revisions in amounts during Q1, Q2 and Q3 of FY2022. In line with this, the figures as of March 31, FY2021 have been retroactively revised.118,010141,939393,100335,374197,114125,414359,491196,071335,070137,786166,357355,26432.1%30.4%32.8%37.1%33.3%37.6%35.0%—4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows項⽬Item営業キャッシュ・フローCash flows from operating activities投資キャッシュ・フローCash flows from investing activitiesフリー・キャッシュ・フローFree cash flows財務キャッシュ・フローCash flows from financing activitiesQ1Q2Q4TotalQ1Q2Q4TotalFY2021Q3百万円（\ million）FY2022Q38,38829,06151,57335,100124,12223,68145,15246,423-12,291-57,924-44,795-3,908-118,918-33,503-16,950-6,671-3,903-28,8636,77831,1925,204-9,82228,20239,752111,818-30,591-29,256-11,17140,800-38,955-5,12334,765——–86．会社概要 / Corporate Outline■会社概要 / Corporate outline会社名Company name上場市場Market銘柄コードStock code設⽴年⽉⽇Established資本⾦（百万円）Capital (\ million)従業員数Headcountグループ会社数Number of group companies本社Head Office事業場Factroy, R&D Center⽀店Branch Offices営業所Sales Offices海外拠点Overseas Offices■株式状況 / Stock information発⾏可能株式総数（株）Total Number of Authorized Shares発⾏済株式総数（株）Number of Shares Issued (Shares)■株式の分布状況 / Shareholder Distribution⾦融機関Japanese financial institution証券会社Japanese securities firmsその他国内法⼈Other Japanese corporations外国⼈Foreign institutions and individuals個⼈・その他Jananese individuals and others⾃⼰株式Treasury stock合計Totalオリンパス株式会社Olympus Corporation東証⼀部1st section of Tokyo Stock Exchange7733ISIN: JP32012000071919年10⽉12⽇October 12, 1919124,64330,879100（本社除く / excluding Olympus Corporation）〒163-0914　東京都新宿区⻄新宿2丁⽬3番1号 新宿モノリスhttps://www.olympus.co.jp/Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japanhttps://www.olympus-global.com/network/⼋王⼦市（東京都）、上伊那郡（⻑野県）、⻄⽩河郡（福島県）Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref.札幌、名古屋、⼤阪、広島、福岡、神⼾Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe新潟、松本、静岡、⾦沢、京都、岡⼭、松⼭、⿅児島Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshimaアメリカ、ドイツ、イギリス、中国、シンガポールほかUSA, Germany, UK, China, Singapore etc所有株式数Number of shares所有株式数の割合Shareholders ratio4,000,000,0001,299,294,333514,488,1969,839,02032,243,567677,083,45351,991,74913,648,3481,299,294,3332021年9⽉30⽇現在As of Sep 30, 20212021年9⽉30⽇現在As of Sep 30, 20212021年9⽉30⽇現在As of Sep 30, 202139.6%0.8%2.5%52.1%4.0%1.1%100.0%9